share_log

8-K/A: Executive Employment Agreement (Amendment)

8-K/A: Executive Employment Agreement (Amendment)

8-K/A:高管聘用協議(修正)
美股SEC公告 ·  10/01 16:11

Moomoo AI 已提取核心訊息

Cassava Sciences, Inc., a biopharmaceutical company, has filed an amendment to its original Form 8-K report with the SEC, detailing the compensation terms for its newly appointed CEO, Richard Barry. The amendment, dated October 1, 2024, follows the initial announcement on September 9, 2024, which did not include these details. Barry's appointment as CEO was effective as of September 6, 2024. The Board approved an executive employment agreement that includes an initial base salary of $675,000 retroactive to July 15, 2024, a target annual bonus of 60% of his base salary, and a stock option award to purchase 600,000 shares at $27.42 per share. The options will vest over four years, contingent upon Barry's continued employment. Additionally, the agreement outlines severance benefits in the event of termination without cause or resignation for good reason, including a year's base salary and medical plan coverage. The full terms of the Employment Agreement are detailed in Exhibit 10.1 attached to the amendment.
Cassava Sciences, Inc., a biopharmaceutical company, has filed an amendment to its original Form 8-K report with the SEC, detailing the compensation terms for its newly appointed CEO, Richard Barry. The amendment, dated October 1, 2024, follows the initial announcement on September 9, 2024, which did not include these details. Barry's appointment as CEO was effective as of September 6, 2024. The Board approved an executive employment agreement that includes an initial base salary of $675,000 retroactive to July 15, 2024, a target annual bonus of 60% of his base salary, and a stock option award to purchase 600,000 shares at $27.42 per share. The options will vest over four years, contingent upon Barry's continued employment. Additionally, the agreement outlines severance benefits in the event of termination without cause or resignation for good reason, including a year's base salary and medical plan coverage. The full terms of the Employment Agreement are detailed in Exhibit 10.1 attached to the amendment.
Cassava Sciences公司是一家生物製藥公司,已向美國證券交易委員會提交了原始8-k表格報告的修正版本,詳細說明了新任CEO Richard Barry的薪酬條款。這項修正日期爲2024年10月1日,是在2024年9月9日的初始公告之後,該公告未包括這些細節。Barry作爲CEO的任命自2024年9月6日生效。董事會批准了一項高管僱傭協議,包括從2024年7月15日起追溯的初始基本工資爲67.5萬美元,目標年度獎金爲其基本工資的60%,以及以每股27.42美元購買60萬股的期權獎勵。這些期權將在四年內按照Barry的繼續工作而行使。此外,協議概述了因無故解僱或由於正當理由辭職而終止的離職福利,包括一年的基本工資和醫療保險。僱傭協議的全部條款在修正版附加的10.1附件中詳細說明。
Cassava Sciences公司是一家生物製藥公司,已向美國證券交易委員會提交了原始8-k表格報告的修正版本,詳細說明了新任CEO Richard Barry的薪酬條款。這項修正日期爲2024年10月1日,是在2024年9月9日的初始公告之後,該公告未包括這些細節。Barry作爲CEO的任命自2024年9月6日生效。董事會批准了一項高管僱傭協議,包括從2024年7月15日起追溯的初始基本工資爲67.5萬美元,目標年度獎金爲其基本工資的60%,以及以每股27.42美元購買60萬股的期權獎勵。這些期權將在四年內按照Barry的繼續工作而行使。此外,協議概述了因無故解僱或由於正當理由辭職而終止的離職福利,包括一年的基本工資和醫療保險。僱傭協議的全部條款在修正版附加的10.1附件中詳細說明。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息